Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: option (487), alternative (391), selection (96), preference (97), pick (130), picking (130), variety (144)

Pembrolizumab_400mg (NSCLC)

Description: Chemotherapy Protocol LUNG CANCER Pembrolizumab (400mg) Regimen • Lung Cancer – Pembrolizumab (400mg) Indication The treatment of untr
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab-400mg.pdf

Pembrolizumab 200mg (NSCLC)

Description: Regimen Chemotherapy Protocol LUNG CANCER Pembrolizumab (200mg) • Lung Cancer – Pembrolizumab (200mg) Indication The treatment of untr
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab-200mg.pdf

Pembrolizumab 400mg (bladder)

Description: Chemotherapy Protocol BLADDER CANCER Pembrolizumab (400mg) Regimen • Bladder – Pembrolizumab (400mg) Indication • Pembrolizumab is ind
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Pembrolizumab-400mg.pdf

Pembrolizumab 200mg (bladder)

Description: Chemotherapy Protocol BLADDER CANCER Pembrolizumab (200mg) Regimen • Bladder – Pembrolizumab (200mg) Indication • Pembrolizumab is ind
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Pembrolizumab-200mg.pdf

Atezolizumab(1680-28days)

Description: Chemotherapy Protocol GENITOURINARY CANCER Atezolizumab (1680mg-28 days) Regimen • Urothelial– Atezolizumab (1680mg-28 days) Indication • This p
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Atezolizumab1680-28days.pdf

Ipilimumab(1mg/kg)-Nivolumab(3mg/kg)

Description: Chemotherapy Protocol RENAL CANCER IPILIMUMAB (1mg/kg)-NIVOLUMAB(3mg/kg) Regimen • Renal – Ipilimumab (1mg/kg)-Nivolumab (3mg/kg) Ind
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Ipilimumab1mgkg-Nivolumab3mgkg.pdf

InP RIVAC (66) cytarabine etoposide ifosfamide rituximab

Description: Chemotherapy Protocol LYMPHOMA CYTARABINE-ETOPOSIDE-IFOSFAMIDE-RITUXIMAB (RIVAC) 66 years and above Inpatient Regimen There are mult
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-RIVAC-66-cytarabine-etoposide-ifosfamide-rituximab.pdf

InP RIVAC (65) cytarabine etoposide ifosfamide rituximab

Description: Chemotherapy Protocol LYMPHOMA CYTARABINE-ETOPOSIDE-IFOSFAMIDE-RITUXIMAB (RIVAC) 65 years and below Inpatient Regimen There are mult
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-RIVAC-65-cytarabine-etoposide-ifosfamide-rituximab.pdf

Pembrolizumab_400mg skin

Description: Chemotherapy Protocol SKIN CANCER Pembrolizumab (400mg) Regimen • Skin – Pembrolizumab (400mg) Indication • Pembrolizumab is recommend
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Pembrolizumab-400mg.pdf

Pembrolizumab_200mg skin

Description: Regimen Chemotherapy Protocol SKIN CANCER Pembrolizumab (200mg) • Skin – Pembrolizumab (200mg) Indication • Pembrolizumab is recommend
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Pembrolizumab-200mg.pdf

381 to 390 of 437

Previous … 37 38 39 40 41 … Next